Navigation Links
TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
Date:3/4/2013

Dundee made its initial investment of USD20m in TauRx in September 2011.  Ned Goodman , President and Chief Executive Officer of Dundee, said: "TauRx has made good use of our initial investment, gaining regulatory clearance to initiate its Phase 3 study program for LMTX™ and establishing a network of experienced service providers to support the studies.  With the first patients now being enrolled into each of the three studies, and with the recent substantial strategic investment from the Genting Berhad group, this seems a highly opportune time to exercise the option we were granted by TauRx at the time of the initial investment and maintain Dundee's 5% interest in this commercially and scientifically promising company."

Professor Claude Wischik , Executive Chairman and Co-Founder of TauRx, said: "It is particularly gratifying to receive this follow-on investment from Dundee.  It made its initial investment at a time of critical importance to the development of both TauRx and our Tau aggregation inhibitor, LMTX™, and we see this additional investment of USD10.5m as a welcome vote of confidence in the commercial potential of our technology from a highly experienced investor.  We continue to believe strongly that Tau aggregation inhibition is the most promising approach to the long-term treatment of AD and other Tau-opathies such as bvFTD.  With expanding patient populations throughout the world due to an aging population, and with products based on beta-amyloid clearance still producing disappointing results in clinical studies, it is now critically important for healthcare systems, patients, their families and their careers to bring an effective treatment for these devastating diseases to market."

About TauRx Therapeutics:

TauRx Therapeutics Ltd was established in Singapore in 2002 with the aim of developing new treatments and diagnostics for a range of neurodegenerative diseases based on an entirely new approach which targets aggregates of abnormal fibres of Tau protein that form inside nerve cells in the brain. The TauRx team have since discovered that LMTX™ could also have beneficial effects in several other neurodegenerative diseases associated with Tau pathology, as well as other protein aggregation disorders including Parkinson's, Huntington's and Frontotemporol Dementia [FTD-Pick's Disease]. The TauRx corporate headquarters are in Singapore and its primary research facilities are in Aberdeen, Scotland.

About Dundee Corporation:

Dundee Corporation is a Canadian independent publicly traded asset management company listed on the Toronto Stock Exchange ("TSX") under the symbol "DC.A". Asset management activities are focused in the areas of the corporation's core competencies and include resources, real estate and infrastructure, and more recently, the agriculture sector. These activities are carried out by Dundee's wholly owned subsidiary, Goodman Investment Counsel Inc. Dundee's capital markets and personal investment advisory services are carried out through the "Dundee Capital Markets" and "Dundee Goodman Private Wealth" divisions of its wholly owned subsidiary, Dundee Securities Ltd.  Dundee also owns and manages direct investments in its core focus areas and other select investments, through ownership, directly and indirectly, of both publicly listed and private companies.


'/>"/>
SOURCE TauRx Pharmaceuticals Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
2. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
3. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
4. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
5. AVANIR Pharmaceuticals To paticipate in two conferences in March
6. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
7. Adamis Pharmaceuticals Prevails in License Dispute Litigation
8. Cumberland Pharmaceuticals Reports 2012 Annual Financial Results
9. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
10. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
11. StockCall Insight into Eli Lilly, Bristol-Myers Squibb, Astex Pharmaceuticals and Raptor Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), ... address serious pulmonary diseases, today announced that it has added ... fibrosis and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the ... Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... Paul M. Bisaro as Impax,s President and ... Board, effective March 27, 2017. Mr. Bisaro will succeed ... Interim President and Chief Executive Officer since December of ... and branded pharmaceutical experience, Mr. Bisaro, 56, is an ...
Breaking Medicine Technology:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... received the CE Certificate of Conformity for the Smart System® 20/20. CE Certification ... the highest industry standards and specifications such as ANSI, ISO and proven test ...
(Date:3/27/2017)... ... March 27, 2017 , ... Advantexe Learning Solutions ... launch of a new research study, The Business Readiness Report. The report explores ... strategy, and the actual success of achieving individual and company goals. , ...
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... ... March 27, 2017 , ... Golden Triangle ... 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of the facility. ... area-residents to celebrate two great years while also familiarizing themselves with the facility. ...
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
Breaking Medicine News(10 mins):